FR1372M - Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
- Google Patents
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR865615ApriorityCriticalpatent/FR1372M/fr
Priority to GB1017462Aprioritypatent/GB978531A/en
Priority to CH328162Aprioritypatent/CH426857A/fr
Application grantedgrantedCritical
Publication of FR1372MpublicationCriticalpatent/FR1372M/fr
208000037265diseases, disorders, signs and symptomsDiseases0.000title1
208000035475disorderDiseases0.000title1
239000002547new drugSubstances0.000title1
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D459/00—Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
FR865615A1961-03-211961-06-21Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
ActiveFR1372M
(fr)
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivite, de l'anxiété et des troubles dus a l'hyperexcitabilité.